Outbreak Investigation Report
CRAB Multi-Hospital Outbreak · EQA Exercise 2024

Step-by-step analysis of the EURGen-RefLabCap EQA exercise — from initial epidemiological data to WGS-based cluster confirmation across six hospitals

Fictitious training scenario 36 WGS isolates 6 Hospitals · Country W ST2 OXA-23 CRAB outbreak

1. Background and Scenario

This report documents the analysis of a fictional multi-hospital outbreak of Carbapenem-Resistant Acinetobacter baumannii (CRAB) designed as part of the EURGen-RefLabCap Multidisciplinary WGS Training Workshop, conducted virtually in January 2024. The exercise was coordinated by Statens Serum Institut / DTU and challenged National Reference Laboratories (NRLs) from across Europe to integrate epidemiological and whole-genome sequencing (WGS) approaches to investigate a complex, multi-hospital outbreak scenario.

Scenario Setting

A fictional National Reference Laboratory (NRL) in Country W receives clinical and epidemiological records for 71 Acinetobacter baumannii cases from six hospitals (Hospitals A–F) spanning January to December 2023. The NRL must determine whether an outbreak is occurring, how many clusters exist, which isolates are related, and how transmission may have spread between hospitals — potentially via patients with travel history to Country Z.

All patient names, hospital identifiers, countries, and isolate data in this exercise are entirely fictitious, created specifically for training purposes. No real patient data or real outbreak information is represented here.

Pathogen Profile: CRAB

Acinetobacter baumannii is a Gram-negative opportunistic pathogen classified by the WHO as a critical-priority organism for the development of new antibiotics. Carbapenem-resistant strains (CRAB) — particularly those carrying OXA-type carbapenemases (most commonly OXA-23) — pose a severe threat in healthcare settings due to their ability to cause difficult-to-treat infections and their propensity for nosocomial transmission. The Global Clone 2 (GC2) lineage, typed as ST2 by the Pasteur MLST scheme, is the most globally disseminated CRAB clone and is the dominant lineage in this exercise.

2. Bioinformatics Methods

Isolate Selection (Inject 1.1 / 1.2)

From the initial 71 clinical records, 36 priority isolates were selected for WGS based on the following metadata criteria:

WGS Analysis Pipeline

Input36 FASTA assemblies (+ raw FASTQ for QC)
MLSTmlst v2.33 — Pasteur scheme (abaumannii_2) + Oxford scheme (abaumannii)
AMR ProfilingAbricate v1.0.1 — CARD database; 49 unique resistance genes identified across 36 isolates
cgMLSTPathogenwatch / Kleborate — core genome MLST types (CT types)
Core SNP AlignmentParsnp v2.1.1 — 75,985 variable SNP sites from core-genome alignment (35 assemblies; AB_43 excluded — no assembly available)
PhylogenyIQ-TREE2 — GTR+G substitution model, 1,000 ultrafast bootstrap replicates; ML tree rooted by outgroup
SNP DistancesIQ-TREE pairwise ML distances (mldist) scaled to genome-wide SNP estimates (× 4 Mb genome)
K/O Locus TypingKleborate / Pathogenwatch — surface polysaccharide locus typing (KL / OCL)
VisualisationD3.js v7 — interactive phylogenetic tree, AMR heatmap, SNP distance matrix, timeline

Note on AB_43

Isolate AB_43 (Hospital B, Inject 3.1) had raw FASTQ reads available but no assembled FASTA, likely due to low coverage or failed assembly. It was excluded from the core-genome alignment and is therefore absent from the phylogenetic tree and SNP matrix. The remaining 35 isolates were used for phylogenetic reconstruction.

3. Inject 1 — Epidemiological Analysis

1.1

Introduction and Case Definition

Received: January 2024 · 71 Acinetobacter baumannii clinical records

The NRL is presented with 71 A. baumannii clinical records from six hospitals (A–F) spanning all of 2023. The initial task is to define a case, construct an epidemic curve, and select priority isolates for WGS.

Working case definition: A patient with a clinical A. baumannii isolate demonstrating carbapenem resistance (or confirmed OXA-23/NDM carriage), admitted to Hospital A–F during January–December 2023.

1.2

Epidemiological Data — EpiCurve Construction

71 clinical records with hospitalization dates, antibiograms, and travel history

Examination of the full case records reveals a temporal clustering of cases in Hospital A beginning in July 2023, with cases extending through the rest of the year. A subset of cases from Hospitals B–F appear later, some with documented patient transfers or travel to Country Z.

Key Metadata Prioritised for Isolate Selection

Workshop participants were asked to rank metadata factors. The most-selected indicators (Survey 1 results, N=20 participants) were:

17
Travel history
16
Hospital of admission
15
Carbapenemase genotype
14
Admission / discharge dates
13
Symptom onset date
9
Hospital transfer history

Based on combined epidemiological assessment, 36 isolates (AB_23–AB_58) were prioritised for WGS, covering all six hospitals and including isolates from patients with Country Z travel history.

Epidemic Curve Interpretation

The epidemic curve for Hospital A shows a propagated (person-to-person) pattern emerging from July 2023, consistent with nosocomial transmission rather than a common-point source. The broader pattern across all six hospitals suggests inter-hospital spread possibly linked to patient transfers and importation events from Country Z.

4. Inject 2 — Hospital A WGS Analysis (18 Isolates)

2.1

Hospital A Sequencing Data Released

Isolates AB_23 – AB_40 · FASTQ + FASTA

Whole-genome sequencing data for all 18 Hospital A isolates (AB_23–AB_40) are released. Participants perform MLST, AMR annotation, cgMLST, and SNP-based phylogenetic analysis.

MLST Results — Hospital A

IsolateMLST PasteurMLST OxfordcgMLSTCarbapenemaseStatus
AB_23, 24, 26, 27, 28, 29, 30, 31ST2ST208CT1451OXA-23Cluster A
AB_25ST1017ST1017OXA-66Sporadic
AB_32ST2ST195CT607OXA-23Inter-cluster
AB_33, 34, 35, 37, 38, 39, 40ST2ST195 / ST1816CT607 / CT2896OXA-23Cluster B
AB_36ST2ST195CT6NDM-2Sporadic

Two Intra-Hospital Clusters Identified

Cluster A

AB_23, 24, 26, 27, 28, 29, 30, 31

  • MLST: ST2 (Pasteur) / ST208 (Oxford)
  • cgMLST: CT1451 (all identical)
  • Carbapenemase: OXA-23
  • Intra-cluster SNPs: 4–210 (closest pairs: AB_23/AB_29 = 4 SNPs; AB_26/AB_27 = 4 SNPs)
  • Epi link: All from Hospital A with overlapping admission dates; direct patient-to-patient contact chains documented
Cluster B

AB_33, 34, 35, 37, 38, 39, 40 (±AB_32)

  • MLST: ST2 (Pasteur) / ST195 or ST1816 (Oxford)
  • cgMLST: CT607 / CT2896
  • Carbapenemase: OXA-23
  • Intra-cluster SNPs: ~1,100–3,600 (more diverse; possible indirect transmission)
  • Epi link: Hospital A, overlapping admissions; patient AB_33 (PT11) linked to multiple cluster members
Sporadic — AB_25

ST1017 / OXA-66 only

Genetically distant from both clusters (millions of SNPs across the full genome — completely different MLST lineage). Not part of the outbreak. Likely healthcare-associated acquisition with a different source.

Sporadic — AB_36

ST2 / NDM-2 (no OXA-23)

Same species and MLST but carries NDM-2 rather than OXA-23. Phylogenetically distinct (~38,000 SNPs from Cluster A). Represents an independent CRAB case, not part of the OXA-23 outbreak.

Survey 2 Results — European NRL Consensus on Hospital A

18 of 19 responding NRLs identified 2 clusters in the Hospital A data. 100% of respondents identified signs of intra-hospital transmission. The most important metadata parameters selected were: hospitalization dates, MLST, cgMLST, carbapenemase genotype, and phylogenetic relation.

5. Inject 3 — Multi-Hospital Expansion

3.1

Hospital B & C Sequencing (10 Isolates)

Isolates AB_41 – AB_50 · Hospitals B and C · Including Country Z patients

Sequencing data for 10 additional isolates from Hospitals B and C are released. Key isolates of interest include those from patients with documented travel to Country Z.

IsolateHospitalMLSTCarbapenemaseCountrycgMLSTFinding
AB_41, AB_42Hospital BST2OXA-23Country ZCT1414Outbreak — linked to Clusters A/B
AB_43Hospital BNo assembly (excluded from tree)
AB_44, AB_45Hospital BST103NDM-4Country ZSporadic — distinct lineage
AB_46, AB_47Hospital CST2OXA-23Country ZCT1451Outbreak — Cluster A related
AB_48, AB_49Hospital CST2OXA-23Country YCT1451Outbreak — Cluster A related
AB_50Hospital CST2OXA-23Country XCT607Cluster B–related / sporadic

The phylogenetic tree integrating Hospitals B and C isolates confirms two critical findings:

  1. AB_46 and AB_47 (Hospital C, Country Z patients) cluster tightly with Hospital A Cluster A isolates — demonstrating inter-hospital spread of the ST2/OXA-23/CT1451 clone, plausibly via patient transfer or healthcare worker movement.
  2. AB_44 and AB_45 (Hospital B, Country Z patients, ST103/NDM-4) are phylogenetically completely distinct. These represent an independent importation event unrelated to the main outbreak. Their branch length in the ML tree is exceptionally long (~1.17 ML distance units), confirming they are genuine outliers.

Country Z — A Complex Signal

Multiple patient sub-groups from Country Z are present in the data. Survey responses found that participants identified: sporadic cases (16/19), intra-hospital transmission (9/19), and inter-hospital transmission (5/19) among Country Z-associated patients. The key distinction is that some Country Z patients carried the same ST2/OXA-23 outbreak clone (AB_41, AB_42, AB_46, AB_47), while others carried an entirely different NDM-4 lineage (AB_44, AB_45).

3.2

Hospital D, E & F Sequencing (8 Isolates)

Isolates AB_51 – AB_58 · Completing the full dataset
IsolateHospitalMLSTCarbapenemaseFinding
AB_51, 52, 53, 54, 55, 56Hospital DST2OXA-23Outbreak — Cluster A/B related
AB_57, AB_58Hospital E & FST2OXA-23Outbreak — Cluster A/B related

The final inject completes the pan-hospital picture. Hospital D isolates (AB_51–AB_56) place within the Cluster A/B supercluster, confirming that the ST2/OXA-23 CRAB outbreak extended well beyond Hospital A. Isolates AB_57 and AB_58 (Hospitals E and F, respectively) also cluster within the outbreak clade, with bootstrap support of 100.

6. Full Genomic Results

6.1 MLST and Lineage Summary

MLST PasteurCountCarbapenemaseInterpretation
ST233OXA-23 (31), NDM-2 (2)Main outbreak lineage (GC2); NDM-2 is sporadic
ST10171OXA-66 (intrinsic only)Unrelated sporadic case (AB_25)
ST1032NDM-4Unrelated Country Z importation (AB_44, AB_45)

6.2 Phylogenetic Structure

The IQ-TREE2 maximum likelihood phylogeny (GTR+G, 1,000 ultrafast bootstrap replicates) resolves four major groupings:

  1. Main outbreak supercluster (bootstrap 100): Contains all 31 OXA-23-positive ST2 isolates across Hospitals A–F. Within this, two sub-clusters are supported:
    • Cluster A: AB_23, 24, 26–31, 46–49, 51–58 — tight ST2/CT1451 clade, closest pairs differ by as few as 4 pairwise SNPs
    • Cluster B: AB_32–35, 37–42 — broader ST2/CT607/CT2896 diversity, consistent with a longer or more indirect transmission chain
  2. AB_36 (NDM-2, ST2): Branches off within the ST2 tree but distinct from both clusters (~38,000 SNPs from Cluster A)
  3. AB_44 / AB_45 (NDM-4, ST103): Extremely long branch (ML distance ~1.17) — completely unrelated to outbreak
  4. AB_25 (ST1017): Outgroup — distinct lineage confirming this is a sporadic non-outbreak case

6.3 AMR Gene Profile

Abricate (CARD database) identified 49 unique resistance genes across 36 isolates (1,017 total hits). The major resistance gene categories are:

Efflux pumps
adeABC, adeIJK, adeL, adeN, abeM, abeS, AmvA, AbaQ, AbaF
Carbapenemases
OXA-23 (31 isolates), OXA-66, NDM-4, NDM-2
Aminoglycosides
APH(3')-Ia, APH(3'')-Ib, APH(6)-Id, AAC(3)-Ia
Sulfonamides
sul1, sul2
Tetracyclines
tet(B)
Beta-lactamases
ADC (intrinsic), TEM-12, OXA-66

Core AMR Signature of Outbreak Isolates

All outbreak cluster isolates (Clusters A and B) share a common AMR backbone: OXA-23 (acquired), OXA-66 (intrinsic), ADC-30, adeABC, adeIJK, tet(B), and sulfonamide resistance genes — consistent with a pan-drug-resistant Hospital clone. AB_25 (ST1017) lacks OXA-23 and carries only the intrinsic A. baumannii resistome. AB_44/AB_45 (ST103/NDM-4) carry a completely different AMR gene set.

6.4 Reconstructed Transmission Timeline

Jan–Jun 2023
Background / Pre-outbreak period A. baumannii cases present in Hospital A at baseline; AB_25 (ST1017) represents a sporadic non-OXA-23 case during this period.
Jul 2023
Outbreak emergence — Hospital A First OXA-23 CRAB cases from Cluster A appear in Hospital A. Index patient(s) cannot be definitively identified from genomic data alone, but epidemiological data supports onset in July.
Jul–Aug 2023
Intra-hospital spread — Hospital A Cluster A expands within Hospital A (AB_23–31). Cluster B cases also emerge in Hospital A (AB_33–40), suggesting either a second introduction or deeper in-hospital evolution of a related clone.
Aug–Sep 2023
Inter-hospital spread — Hospital B & C ST2/OXA-23 isolates appear in Hospitals B and C. Patients with Country Z travel history (AB_41, AB_42, AB_46, AB_47) carry the same outbreak clone, suggesting bidirectional spread (importation from Country Z and/or export to Country Z-linked patients).
Sep–Dec 2023
Full multi-hospital outbreak — Hospitals D, E, F The ST2/OXA-23 outbreak clone is detected across all six hospitals. Hospital D (AB_51–56) is most heavily affected. Hospitals E (AB_57) and F (AB_58) each contribute one isolate.
Throughout 2023
Concurrent sporadic cases AB_36 (NDM-2), AB_44/45 (NDM-4, ST103), and AB_50 (ST2, Country X) represent independent events unrelated to the main ST2/OXA-23 outbreak cluster.

7. Conclusions

Primary Conclusion

This exercise demonstrates a confirmed multi-hospital outbreak of ST2 (GC2) OXA-23-positive CRAB originating in Hospital A and spreading to all five additional hospitals. The outbreak involved at least two phylogenetically distinct sub-clusters (Cluster A and Cluster B) within the ST2/OXA-23 lineage. Inter-hospital transmission is strongly supported by phylogenomics and is partly linked to patient movement and travel from Country Z.

🦠

Outbreak clone confirmed

33/36 isolates belong to ST2 (Pasteur) with OXA-23 carbapenemase. All cluster within a single ML phylogenetic clade with bootstrap support of 100.

🏥

Multi-hospital spread

The ST2/OXA-23 clone was detected in all six hospitals. Inter-hospital links are supported both by genomic clustering and by patient transfer / travel history data.

🌍

Country Z — complex signal

Country Z-associated patients carried two distinct organisms: the outbreak clone (ST2/OXA-23, Cluster A) AND an unrelated NDM-4 strain (ST103). Careful genomic discrimination was essential to avoid misclassifying the NDM-4 cases as part of the outbreak.

🔬

Sporadic cases identified

AB_25 (ST1017), AB_36 (NDM-2), AB_44/45 (NDM-4/ST103), and AB_50 are not part of the outbreak. WGS correctly excluded these from the transmission cluster that epi data alone might have grouped together.

🧬

WGS adds critical resolution

MLST alone (all isolates = ST2) could not distinguish the two sub-clusters or the sporadic NDM-2 case. cgMLST and SNP-level analysis were required for definitive cluster assignment.

📊

European NRL consensus

18/19 participating NRLs independently reached the same conclusion: 2 intra-hospital clusters in Hospital A, with 100% agreement on intra-hospital transmission — validating the robustness of WGS-based outbreak analysis.

Key Lessons from the Exercise

Explore Interactive Dashboard → ← Back to Home